Will Intuitive Surgical Stock Witness Continued Growth Momentum?
Intuitive Surgical (ISRG) has returned approximately 48.2% YTD (year-to-date), surpassing SPY as well as the Health Care Select Sector SPDR Fund (XLV) by enormous margins.
Intuitive Surgical (ISRG) has witnessed a recent rally, and it reached an all-time high of $940.4 on June 20, 2017.
On May 30, 2017, Intuitive Surgical (ISRG) announced that it received FDA (US Food and Drug Administration) approval of its new da Vinci X robotic surgical system.
Intuitive Surgical’s da Vinci Sp is the latest technological innovation in the company’s surgical systems.
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.
Most of Stryker’s emerging market sales are from China. However, Europe and emerging markets sales have witnessed high growth in recent quarters.
In March 2017, Stryker (SYK) announced the commercial launch of its robotic-arm assisted total knee application to be used with its MAKO system.
At the end of 1Q17, Stryker had placed 350 robots in the United States and completed about 1,400 MAKO total knee replacements.
In a Reuters survey of 27 brokerage companies, about 63.0% of analysts have rated Stryker a “buy,” and 26.0% have rated it a “hold.”
On June 14, 2017, in a Reuters survey including 25 brokerage companies, 56% of the analysts gave Medtronic a “buy” rating, while 44% rated it as a “hold.”
In January 2017, Medtronic received FDA IDE approval to initiate a study of its IN.PACT AV Access DCB for a new indication in ESRD patients.
On June 6, 2017, Medtronic (MDT) received the Health Canada license for its SureTune3 software for DBS (deep brain stimulation) therapy.
On April 18, Medtronic announced the divestiture of its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health.
Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections.
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.
Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.